Cargando…

Resection of “down-staged” advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report

Sorafenib and lenvatinib are currently standard treatments for advanced hepatocellular carcinoma (HCC); however, the therapeutic effect is unsatisfying. Indeed, very few patients with HCC under sorafenib treatment were eligible for surgery in the past ten years. In addition, there is no report of a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Zhenyu, Zhu, Keyun, Yang, Xuejiao, Zhou, Hongyuan, Chen, Ping, Yu, Ge, Zhu, Xiaolin, Cui, Yunlong, Song, Tianqiang, Li, Qiang, Li, Huikai, Zhang, Ti
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799223/ https://www.ncbi.nlm.nih.gov/pubmed/35117862 http://dx.doi.org/10.21037/tcr-19-3019

Ejemplares similares

Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial
por: Hou, Zhenyu, et al.
Publicado: (2020)

The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib
por: Wang, Huaqi, et al.
Publicado: (2021)

Apatinib is effective for treatment of advanced hepatocellular carcinoma
por: Kong, Yinlong, et al.
Publicado: (2017)

Drug-Related Hypertension Associated with the Efficacy of Apatinib on Hepatocellular Carcinoma
por: Yang, XueJiao, et al.
Publicado: (2020)

Different but synergistic effects of bone marrow-derived VEGFR2(+) and VEGFR2(−)CD45(+) cells during hepatocellular carcinoma progression
por: Zhu, Xiaolin, et al.
Publicado: (2017)

Drug-related adverse events potentially predict the efficacy of apatinib on advanced hepatocellular carcinoma
por: Gu, Xiaoying, et al.
Publicado: (2022)

Decreased expression of acetyl‐CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma
por: Sun, Lin, et al.
Publicado: (2017)

Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30
por: Guo, Zhigui, et al.
Publicado: (2016)

Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models
por: You, Abin, et al.
Publicado: (2016)

Apatinib as an alternative therapy for advanced hepatocellular carcinoma
por: Zhang, Xi-Hao, et al.
Publicado: (2020)

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety
por: Liao, Zhichao, et al.
Publicado: (2019)

A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
por: Ju, Wu-tong, et al.
Publicado: (2022)

Apatinib inhibits VEGFR-2 and angiogenesis in an in vivo murine model of nasopharyngeal carcinoma
por: Peng, Qiu-Xia, et al.
Publicado: (2017)

LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma
por: Yu, Ge, et al.
Publicado: (2022)

Apatinib Induces Ferroptosis of Glioma Cells through Modulation of the VEGFR2/Nrf2 Pathway
por: Xia, Liang, et al.
Publicado: (2022)

Apatinib monotherapy for advanced VEGFR-2-negative nasopharyngeal carcinoma: A case report
por: Jin, Jun, et al.
Publicado: (2019)

A Case of Curative Treatment with Apatinib and Camrelizumab Following Liver Resection for Advanced Hepatocellular Carcinoma
por: Huang, Julu, et al.
Publicado: (2023)

Case Report: Gastrointestinal PEComa With TFE3 Rearrangement Treated With Anti-VEGFR TKI Apatinib
por: Xu, Jiaming, et al.
Publicado: (2020)

Therapeutic Potential of Apatinib Against Colorectal Cancer by Inhibiting VEGFR2-Mediated Angiogenesis and β-Catenin Signaling
por: Cai, Xiaomin, et al.
Publicado: (2020)

Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma
por: Ma, Bingqi, et al.
Publicado: (2020)

High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma
por: Ma, Bingqi, et al.
Publicado: (2021)

MiR-425-5p promotes invasion and metastasis of hepatocellular carcinoma cells through SCAI-mediated dysregulation of multiple signaling pathways
por: Fang, Feng, et al.
Publicado: (2017)

Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer
por: Xie, Chunfeng, et al.
Publicado: (2021)

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma
por: Gan, Leijuan, et al.
Publicado: (2023)

Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma
por: Liu, Kuisheng, et al.
Publicado: (2017)

Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection
por: Li, Qingli, et al.
Publicado: (2021)

Correction to: Apatinib triggers autophagic and apoptotic cell death via VEGFR2/STAT3/PD-L1 and ROS/Nrf2/p62 signaling in lung cancer
por: Xie, Chunfeng, et al.
Publicado: (2021)

VEGFR-2 Inhibitor Apatinib Hinders Endothelial Cells Progression Triggered by Irradiated Gastric Cancer Cells-derived Exosomes
por: Li, Guangxin, et al.
Publicado: (2018)

An Oral Small Molecule VEGFR2 Inhibitor, Apatinib, in Patients with Recurrent or Refractory Cervical Cancer: A Real World Study
por: Li, Ning, et al.
Publicado: (2020)

Five-CpG-based prognostic signature for predicting survival in hepatocellular carcinoma patients
por: Fang, Feng, et al.
Publicado: (2018)

Adjuvant apatinib treatment after resection of hepatocellular carcinoma with portal vein tumor thrombosis: a phase II trial
por: Sun, Hui-Chuan, et al.
Publicado: (2020)

Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma
por: Wang, Hongzhi, et al.
Publicado: (2022)

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
por: Yang, Qing, et al.
Publicado: (2023)

Hepatocellular carcinoma successfully treated with ALPPS and apatinib: A case report
por: Liu, Ling, et al.
Publicado: (2019)

Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma
por: Gu, Huiying, et al.
Publicado: (2020)

The radiosensitive effect of apatinib for hepatocellular carcinoma patient with big paraspinal metastasis: A case report
por: Zhu, Hong, et al.
Publicado: (2018)

Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma
por: Yang, Chaoxu, et al.
Publicado: (2018)

Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway
por: Song, Yong-An, et al.
Publicado: (2019)

Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial
por: Xia, Yongxiang, et al.
Publicado: (2022)

Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study
por: He, Wei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_etf89oci75khnrf0lso2tjracd